Results 51 to 60 of about 2,234,350 (412)

Obstetric and long-term kidney outcomes in renal transplant recipients: a 40 year single-centre study [PDF]

, 2016
Female renal transplant recipients of childbearing age may ask what the outcomes are for pregnancy and whether pregnancy will affect graft function. We analyzed obstetric and transplant outcomes among renal transplant recipients in our center who have ...
Brennand, Janet E., Deighan, Christopher J., Geddes, Colin C., Gorrie, Morag, Mark, Patrick B., McNeill, Susan H., Stoumpos, Sokratis   +6 more
core   +1 more source

Comprehensive Investigation of the Caveolin 2 Gene: Resequencing and Association for Kidney Transplant Outcomes [PDF]

, 2013
Caveolae are plasma membrane structures formed from a complex of the proteins caveolin-1 and caveolin-2. Caveolae interact with pro-inflammatory cytokines and are dysregulated in fibrotic disease.
Borrows, Richard, Conlon, Peter J, Courtney, Aisling E, Duffy, Seamus, Maxwell, Alexander P, McCaughan, Jennifer A, McKnight, Amy Jayne, O'Hagan, Thomas   +7 more
core   +2 more sources

Biomarkers in solid organ transplantation: establishing personalized transplantation medicine. [PDF]

, 2011
Technological advances in molecular and in silico research have enabled significant progress towards personalized transplantation medicine. It is now possible to conduct comprehensive biomarker development studies of transplant organ pathologies ...
Khatri, Purvesh, Roedder, Silke, Sarwal, Minnie M, Vitalone, Matthew   +3 more
core   +3 more sources

TRPM8 levels determine tumor vulnerability to channel agonists

Molecular Oncology, EarlyView.
TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo, Francesco Giuseppe Carbone, Kristi Buzo, Nicole Annesi, Sacha Genovesi, Annalisa Lorenzato, Karen Widmann, Michela Libergoli, Elisa Marmocchi, Giovanni Bertalot, Alberto Brolese, Mauro Giulio Papotti, Luca Molinaro, Orazio Caffo, Mattia Barbareschi, Alberto Bardelli, Alessandro Romanel, Sabrina Arena, Andrea Lunardi   +18 more
wiley   +1 more source

Report on post-transplantation cancer in southeast Asia from the Thai kidney transplantation cohort

Scientific Reports
Post-transplantation cancer is a significant cause of mortality among kidney transplant recipients (KTR). The incidence of post-transplantation cancer varies based on geographic region and ethnicity.
Suthanit Laowalert, Nattakan Naitook, Kesawan Boonnim, Uayporn Prungrit, Nidjaree Aekkachaipitak, Pornpawee Lamjantuek, Wisit Liwlompaisan, Rungrote Khunprakant, North Techawathanawanna, Viroon Mavichak, Suwasin Udomkarnjananun   +10 more
doaj   +1 more source

Cost of lifetime immunosuppression coverage for kidney transplant recipients. [PDF]

, 2008
On January 1, 2000, Medicare extended the coverage of immunosuppression medications from 3 years to life for elderly and disabled kidney transplant recipients.
Page, Timothy F, Woodward, Robert
core   +1 more source

Experimental rat models of chronic allograft nephropathy: a review [PDF]

, 2014
Chronic allograft nephropathy (CAN) is the leading cause of late allograft loss after renal transplantation (RT), which continues to remain an unresolved problem. A rat model of CAN was first described in 1969 by White et al. Although the rat model of RT
Haylor, John, Shrestha, Badri
core   +2 more sources

Bortezomib in Kidney Transplantation [PDF]

Journal of Transplantation, 2010
Although current therapies for pretransplant desensitization and treatment of antibody-mediated rejection (AMR) have had some success, they do not specifically deplete plasma cells that produce antihuman leukocyte antigen (HLA) antibodies. Bortezomib, a proteasome inhibitor approved for the treatment of multiple myeloma (a plasma cell neoplasm ...
Rajeev Raghavan, Abdallah Jeroudi, Katafan Achkar, A. Osama Gaber, Samir J. Patel, Abdul Abdellatif   +5 more
openaire   +3 more sources

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

Long-term clinical outcome of patients with severe atherosclerotic renal artery stenosis after percutaneous transluminal renal angioplasty

Renal Replacement Therapy, 2018
Background In the patients with severe atherosclerotic renal artery stenosis (ARAS), the evaluation of long-term clinical outcome after percutaneous transluminal renal angioplasty (PTRA) has yet been insufficient.
Yasuhiro Mochida, Takayasu Ohtake, Yusuke Miyashita, Kunihiro Ishioka, Machiko Oka, Kyoko Maesato, Hidekazu Moriya, Sumi Hidaka, Shigeru Saito, Shuzo Kobayashi   +9 more
doaj   +1 more source